Milestone Pharmaceuticals Outlines 2025 Corporate Priorities
- The PDUFA date for CARDAMYST™ (etripamil) nasal spray is set for March 27, 2025, aimed at treating Paroxysmal Supraventricular Tachycardia (PSVT).
- Current plans include a commercial launch for PSVT anticipated in mid-2025.
- Milestone is planning to initiate a Phase 3 study in patients with Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) early in 2025.
Milestone Pharmaceuticals Inc. (NASDAQ: MIST), a company dedicated to developing innovative cardiovascular therapies, has shared key updates regarding its strategic vision for the year 2025. This year is expected to be transformative as Milestone prepares for potential FDA approval of its lead product, CARDAMYST, which is designed to support patients managing PSVT independently.
"2025 aims to be a crucial turning point for Milestone as we advance toward the potential FDA approval of CARDAMYST. This product will empower patients to manage their PSVT episodes without needing constant healthcare provider availability," stated Joseph Oliveto, the President and Chief Executive Officer of Milestone Pharmaceuticals. The company is excited about the planned investor event scheduled for February 25, where they will delve into these developments further.
CARDAMYST: A Solution for Paroxysmal Supraventricular Tachycardia
The upcoming PDUFA target date is set for March 27, 2025. CARDAMYST™, which is an etripamil nasal spray, is under review by the U.S. Food and Drug Administration (FDA) for tackling PSVT. Notably, an advisory committee meeting to discuss the NDA application is not anticipated, highlighting confidence in the submission.
Milestone is diligently preparing for a commercial launch of CARDAMYST in mid-2025, pending FDA approval. The company has recently appointed Jeff Moore as Vice President of Sales, enhancing the talent pool responsible for the launch strategy. They plan to establish a sales team comprised of about sixty professionals with a primary focus on clinical cardiologists and electrophysiologists.
Investor Event Scheduled for February 25
In conjunction with their corporate update, Milestone will host a live investor event aimed at discussing the commercial strategy for CARDAMYST. Joseph Oliveto and Lorenz Muller, the Chief Commercial Officer, will present crucial insights during this event. To learn more about the event, interested parties can reach out to Sam Matel directly.
As Milestone gears up for the potential launch, they are also preparing for their presence at notable upcoming medical conferences. Assuming approval is granted as per the PDUFA timeline, Milestone intends to showcase CARDAMYST at the American College of Cardiology Annual Meeting set for March 29 to 31, 2025, and at the Heart Rhythm Society Annual Meeting scheduled for April 24 to 27, 2025.
Advancing Research for Atrial Fibrillation with Etripamil
Milestone remains committed to expanding its research portfolio. They are making strides in preparing a Phase 3 pivotal trial aimed at addressing AFib-RVR patients, which is expected to commence with enrollment in the first half of 2025. The trial will explore the efficacy of etripamil nasal spray administered at home, building on feedback from the FDA.
Understanding Etripamil
Etripamil, Milestone's flagship investigational product, is classified as a calcium channel blocker providing an innovative approach for managing both PSVT and AFib-RVR. Its unique formulation allows for self-administration, granting patients autonomy in emergencies without necessitating immediate medical supervision. Should it receive FDA approval, etripamil is positioned to enhance on-demand care options, facilitating better health management for patients.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) focuses on creating ingenious cardiovascular solutions to improve the lives of those with serious heart conditions. Their dedication to understanding and addressing unmet patient needs translates to the development of therapies designed for patient self-management, with a firm belief that every person should have an active role in managing their health.
Frequently Asked Questions
What is the main focus of Milestone Pharmaceuticals in 2025?
In 2025, Milestone Pharmaceuticals is primarily focused on advancing the development of CARDAMYST and expanding its commercial strategies for its cardiovascular products.
What are the expected outcomes from the investor event on February 25?
The investor event will provide insights into the commercial strategy for CARDAMYST and updates on Milestone's progress in product development.
When is the PDUFA date for CARDAMYST?
The PDUFA date for CARDAMYST is March 27, 2025, which is when the FDA is expected to make a decision on approval.
What are the benefits of etripamil for patients?
Etripamil offers a self-administered treatment option, allowing patients to manage PSVT episodes more effectively without requiring immediate medical attention.
How is Milestone preparing for upcoming medical conferences?
Assuming FDA approval, Milestone is preparing to showcase CARDAMYST at significant medical conferences, enhancing visibility and awareness within the healthcare community.
